Please login to the form below
brodalumab
This page shows the latest brodalumab news and features for those working in and with pharma, biotech and healthcare.
Sun Pharma passes milestone with novel psoriasis drug approval
IL-23-selective follow-up Tremfya (guselkumab) as well as three IL-17 inhibitors - Novartis’ Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) and Valeant Pharma’s Siliq (brodalumab).
Latest news
-
AbbVie reports more solid data for would-be psoriasis blockbuster
ixekizumab) and Valeant’s Siliq (brodalumab).
-
Lilly claims another EU okay for Taltz
leader. A third IL-17 drug - Valeant’s Siliq (brodalumab) - was launched in the third quarter in the US at a discount to Cosentyx and Taltz but the company has yet
-
European Commission backs LEO Pharma’s Kyntheum
Novel biologic therapies such as brodalumab mean that achieving completely clear skin can now be a reality for people with moderate-to-severe psoriasis.”. ... Additionally, across all three trials, 56-61% of patients reported the skin condition no
-
Biosimilars eat into J&J's Remicade sales
brodalumab) - which claimed an earlier-than-expected FDA approval for psoriasis last week.
-
Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog
Meanwhile among other positive opinions granted by the CHMP was one for Leo Pharma's interleukin-17 inhibitor Kyntheum (brodalumab) - acquired from AstraZeneca - for plaque psoriasis.
More from news
Approximately 9 fully matching, plus 34 partially matching documents found.
Latest Intelligence
-
Pharma deals in September 2015
Brodalumab is phase III complete, but is thought to have been cast off due to concerns raised over links to the drug and suicidal thoughts. ... Collaboration - discovery. 500. AstraZeneca. Valeant Pharmaceuticals. Brodalumab for psoriasis, ready for
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
-
Scientific Director
-
Great salary and bebefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
-
Senior Medical Writer
-
Great salary and benefits
-
Senior Medical Writer
-
Great salary and bebefits
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Account Manager – Med Comms – London
-
Salary TBC
-
Senior Programme Executive
-
Salary TBC
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
Subscribe to our email news alerts
PMHub
StratX
StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...
Latest intelligence
- No incentive for a cure
- The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
Quick links
Infographics
